InMed Pharmaceuticals Inc.

INM

NASDAQ

Healthcare

Biotechnology

Vancouver, BC, CA13 employeesinmedpharma.com

$0.64

-0.04(-5.25%)

Mkt Cap $1M

$0.61

$3.87

52-Week Range

At a Glance

AI-generated

8-K

InMed Pharmaceuticals filed a prospectus supplement on April 3, 2026, to sell common shares worth up to $1,213,648 under its existing At The Market Offering Agreement with H.C. Wainwright & Co.

$1M

Market Cap

$2.4B

Revenue

-$4.2B

Net Income

Employees13

Fundamentals

How The Business Makes Money

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Industry Biotechnology

Activity

What Changed Recently

Delisting

Mar 29, 2026

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.** On March 27, 2026, InMed Pharmaceuticals Inc. (the "Compa

Impairment

Mar 5, 2026

. 1 Item 7.01 Regulation FD Disclosure. On March 6 , 2026, the Company issued a press release regarding the Company’s wind down of commercial operations. A copy

Other Event

Apr 2, 2026

Other Events.** ** ** As previously reported, InMed Pharmaceuticals Inc. (the “Company”) entered into an At The Market Offering Agreement dated April 7, 2022, a

Regulation FD

Mar 22, 2026

, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act,

Regulation FD

Mar 8, 2026

, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act,

Company Profile

CIK0001728328

ISINCA4576377002

CUSIP457637601

Phone604 669 7207

Address815 West Hastings Street, Vancouver, BC, V6C 1B4, CA

SEC EDGAR